P-CD70-ALLO1

N/A

Report date: 2024/03/18 11:13:30

Base Information

Drug NameP-CD70-ALLO1
Drug Alias NameP-CD70-ALLO1
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD70
TargetsCD70 antigen
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPoseida Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdPoseida Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A